The Potential of Adeno-associated virus Vector Gene Therapy for Achromatopsia

Authors

  • Farianti Wiranda Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
  • Grace Marta Tanjung Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
  • Yudha Pandapotan Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia.
  • Santi Anugrahsari Departemen Mata, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia. https://orcid.org/0000-0001-6712-6968

DOI:

https://doi.org/10.36452/JMedScientiae.v2i2.2828

Keywords:

Achromatopsia, gen therapy, AAV vectors

Abstract

Achromatopsia, also known as color blindness, is the inability to distinguish certain colors. Where this is the inability of the eye cone cells to capture a certain color spectrum due to genetic factors and certain diseases. Abnormalities in the anatomical structure of the eye located on the retina and inherited recessively. These mutations lead to functional loss and slowly progressive degeneration of the cone photoreceptors. Treatment for color blindness is currently limited to genetic counseling, glasses or colored contact lenses. Genetic therapy methods are currently being developed targeting the retinal organs using recombinant adenovirus vectors. The results of research conducted on animals found an improvement in the function of cone cells so that gene therapy is a promising modality in the future.

Downloads

Published

2023-08-14

How to Cite

Wiranda, F., Tanjung, G. M. ., Pandapotan, Y., & Anugrahsari, S. (2023). The Potential of Adeno-associated virus Vector Gene Therapy for Achromatopsia . Jurnal MedScientiae, 2(2). https://doi.org/10.36452/JMedScientiae.v2i2.2828

Issue

Section

Literatur Review